A phase 3, randomised, open-label, crossover study to compare HFA vs CFC pMDI formulations of budesonide on methacholine hyper-reactivity in patients with stable, persistent, mild to moderate asthma.
Phase of Trial: Phase III
Latest Information Update: 06 Nov 2012
At a glance
- Drugs Budesonide (Primary)
- Indications Asthma
- Focus Therapeutic Use
- Sponsors AstraZeneca
- 06 Nov 2012 Trial phase changed from IV to III as reported by ClinicalTrials.gov.
- 15 Mar 2012 Planned number of patients changed from 60 to 95 as reported by EudraCT.
- 22 Sep 2010 Results presented at the 20th Annual Congress of the European Respiratory Society.